Document Security Systems, Inc. (DSS) News

Document Security Systems, Inc. (DSS): $0.25

0.02 (+7.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DSS to Watchlist
Sign Up

Industry: Shipping


Ranked

of 45

in industry

Filter DSS News Items

DSS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest DSS News From Around the Web

Below are the latest news stories about DSS INC that investors may wish to consider to help them evaluate DSS as an investment opportunity.

DSS And 3 Other Stocks Under $1 Insiders Are Aggressively Buying

The Dow Jones closed lower by over 100 points on Wednesday after the Fed raised interest rates by 50 bps. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. DSS The Trade: DSS, Inc. (NYSE: DSS ) Director Heng Fai Ambrose Chan bought a total of 334,921 shares at an average price of $0.23. To acquire these shares, it cost around $75.89 thousand. What’s Happening: The company’s stock dipped around 43% over...

Benzinga | December 15, 2022

DSS: Q3 Results Were Hurt By Cost Increases for Packaging and Unrealized Losses on Investments

By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT DSS (NYSE:DSS) reported revenues of $11.9 million, up 160% from a year ago’s $4.6 million. Direct marketing and printed products both contributed 42% of revenues at $$5.0 million and $4.9 million respectively. However, printed product sales were up 47% and up 24% sequentially while direct marketing was up 411% year over year, but down

Yahoo | November 17, 2022

Impact BioMedical Scientific Partner GRDG Sciences to be Featured in New Documentary

Impact BioMedical is a wholly owned subsidiary of DSS “A Real-Life Mission Impossible” — Global Research and Discovery Group steps in the spotlight for documentary, “The BioQuest” — Filming to start December 3 ROCHESTER, N.Y., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Daryl Thompson, founder of GRDG Sciences LLC (“GRDG”) in Winter Haven, Florida, has spent a career working just out of the spotlight and inventing biological and medical technologies that, when fully deployed, could better the lives of peo

Yahoo | October 19, 2022

DSS: DSS Plans Three Spin Offs in the Next Nine Months, With the First Potentially Worth $160 Million

By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT Shareholders can look forward to three potential spin-offs at DSS (NYSE:DSS) in the next nine months. Investors are aware of the imminent spin-off of Impact Biomedical, as its red herring has been filed, and it is in the comments phase with the SEC. However, a spin-off of American Pacific Bancorp could actually happen more quickly as it

Yahoo | September 22, 2022

DSS Receives New York Stock Exchange Notice Regarding Late Form 10-Q Filing

ROCHESTER, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced it received a notice (the "Notice") stating that the Company is not in compliance with the NYSE American’s continued listing requirements under the timely filing crit

Yahoo | August 30, 2022

Impact BioMedical Develops Quantum Antihistamine

ROCHESTER, N.Y., July 26, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced that less than a year after successfully synthesizing its first Quantum-based compound, Impact Biomedical, Inc. and its research partner Global Research and Discovery

Yahoo | July 26, 2022

DSS stock pops on licensing deal with ProPhase Labs (NYSE:DSS)

DSS (DSS) shares popped around 17% after the company announced on Thursday the licensing of Impact BioMedical''s Linebacker portfolio to ProPhase Labs (PRPH).Global BioLife, a subsidiary…

Seeking Alpha | July 22, 2022

DSS Announces Licensing of Impact BioMedical’s Linebacker Portfolio to ProPhase Labs

ROCHESTER, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced Global BioLife, Inc. (“Global BioLife”), a subsidiary of the Company’s wholly owned subsidiary Impact BioMedical, Inc. (“Impact BioMedical”), executed a license agree

Yahoo | July 21, 2022

DSS Strengthens and Expands Board with Appointment of Two Independent Directors

ROCHESTER, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy, today announced the expansion of its Board of Directors with the appointment of two independent directors, Frankie Wong, a 20-year veteran of public-company financial reporting, and

Yahoo | July 13, 2022

Impact BioMedical Announces License Agreement with ProPhase Labs to Produce and Distribute Viral-Fighting Compound Equivir

HENRIETTA, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research and Discovery Group Sciences (GRDG), announced today that it signed a license agreement with ProPhase Labs (NASDAQ: PRPH) for Equivir, which has shown potential as a treatment to limit the occurrence of or reduce the risk or severity of viral outbreaks. “We are excited to team up with ProPhase Labs, who

Yahoo | June 28, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6227 seconds.